The Impact of Preexisting or Acquired Kaposi Sarcoma Herpesvirus Infection in Kidney Transplant Recipients on Morbidity and Survival
Article first published online: 22 SEP 2009
© 2009 The Authors Journal compilation © 2009 The American Society of Transplantation and the American Society of Transplant Surgeons
American Journal of Transplantation
Volume 9, Issue 11, pages 2580–2586, November 2009
How to Cite
Francès, C., Marcelin, A. G., Legendre, Ch., Chevret, S., Dussaix, E., Lejeune, J., Euvrard, S., Bigorie, A., Schulz, T. F., Agbalika, F., Lebbé, C. and the skin and organ transplantation group of the French Society of Dermatology (2009), The Impact of Preexisting or Acquired Kaposi Sarcoma Herpesvirus Infection in Kidney Transplant Recipients on Morbidity and Survival. American Journal of Transplantation, 9: 2580–2586. doi: 10.1111/j.1600-6143.2009.02816.x
- Issue published online: 15 OCT 2009
- Article first published online: 22 SEP 2009
- Received 27 February 2009, revised 29 July 2009 and accepted for publication 29 July 2009
- Human herpesvirus type 8;
- Kaposi's sarcoma;
- Kaposi sarcoma herpesvirus;
- kidney transplantation
The impact of preexisting or acquired Kaposi sarcoma herpesvirus (KSHV) infection in kidney transplant recipients was evaluated in a prospective study. Serum collected from kidney donors and recipients before transplantation were tested for antibodies against KSHV latent nuclear antigen. Three groups of recipients were defined: group A (KSHV+), group B (KSHV−, KSHV+ donor) and group C (donor and recipient KSHV−). Blood was collected from recipients, every 3 months for 3 years, for KSHV viremia (groups A and B), quantitative (group A) and qualitative serology (group B). Data of group C recipients were extracted from a French database. The prevalence of KSHV antibodies was 1.1% in donors and 3.2% in recipients. There were respectively 161, 64 and 4744 recipients in groups A, B and C.
In group A, 13% developed Kaposi's sarcoma (KS). Age >53.5 years (p = 0.025) and black skin (p = 0.0054) were associated with KS development. In group B, three recipients developed clinical manifestations related to KSHV infection. There was no difference in terms of survival and graft loss between the three groups. In conclusion, although kidney recipients should be aware of the additional risk of KSHV morbidity, KSHV+ recipients should not be systematically excluded from kidney transplantation.